Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
71.71 USD +0.27% Intraday chart for Axsome Therapeutics, Inc. +5.61% -9.90%
Apr. 02 Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing MT
Apr. 01 Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder CI

Evolution of the average Target Price on Axsome Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

218b5.pFupWvAqD-Qx7E5U46t4onc9pZnutjVsmAX4x1asdKE.4HbvOZRIZNd6lD4bpN4BlAVfy9Sl7gE20DbBow7kH9nqbto0m2FuqF6aIQ~73de531b8ea0b9f565a35368ab1165e2

Analyst Recommendations on Axsome Therapeutics, Inc.

Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing MT
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating MT
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108 MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept MT
Mizuho Raises PT on Axsome Therapeutics to $112 From $90 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
UBS Initiates Axsome Therapeutics With Buy Rating, $111 Price Target MT
RBC Initiates Axsome Therapeutics at Outperform With $126 Price Target, Cites Auvelity Launch, Stable Cash Flows From Sunosi, 'Underappreciated Pipeline Optionality' MT
Piper Sandler Raises Price Target on Axsome Therapeutics to $113 From $90, Maintains Overweight Rating MT
Citigroup Initiates Axsome Therapeutics With Buy Rating, Price Target is $125 MT
Mizuho Reduces Price Target on Axsome Therapeutics to $90 From $100, Reflecting Changes in the Model, Keeps Buy Rating MT
Mizuho Increases Price Target on Axsome Therapeutics to $100 From $95, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Axsome Therapeutics to $180 From $190, Keeps Buy Rating MT
BofA Securities Upgrades Axsome Therapeutics to Neutral From Underperform, Adjusts Price Target to $81 From $59 MT
Piper Sandler Upgrades Axsome Therapeutics to Overweight From Neutral, Adjusts Price Target to $90 From $70 MT
HC Wainwright Adjusts Axsome Therapeutics Price Target to $190 From $200, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Axsome Therapeutics to $90 From $87, Maintains Equalweight Rating MT
Mizuho Ups Price Target on Axsome Therapeutics to $95 From $84, Keeps Buy Rating MT
Guggenheim Adjusts Price Target on Axsome Therapeutics to $100 From $90, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Axsome Therapeutics to $87 From $83, Maintains Equal-Weight Rating MT
Morgan Stanley Adjusts Axsome Therapeutics' Price Target to $83 From $85, Keeps Equalweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
71.71 USD
Average target price
121.1 USD
Spread / Average Target
+68.91%
High Price Target
190 USD
Spread / Highest target
+164.96%
Low Price Target
90 USD
Spread / Lowest Target
+25.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Axsome Therapeutics, Inc.

Mizuho Securities
HC Wainwright
Citigroup
RBC Capital Markets
Baird
UBS
Piper Sandler
BofA Securities
Morgan Stanley
Guggenheim
SMBC Nikko
BTIG
SVB Securities LLC
Loop Capital
Jefferies & Co.
Truist Securities
Cantor Fitzgerald
Cowen
Berenberg Bank
SVB Leerink
Ladenburg Thalmann

Ratings for Axsome Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. Consensus Axsome Therapeutics, Inc.